A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

231

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

May 3, 2025

Study Completion Date

May 3, 2025

Conditions

Atopic Dermatitis

Interventions

DRUG

Rocatinlimab

Vial supplied as a single-use preservative free solution for SC injection.

DRUG

Rocatinlimab

Autoinjector for SC injection.

Trial Locations (3)

Fortrea Clinical Research Unit - Daytona Beach, Daytona Beach

Fortrea Clinical Research Unit - Dallas, Dallas

Fortrea Clinical Research Unit Inc. - Madison, Madison